Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Program for EoE on May 29, 2024

Eupraxia Pharmaceuticals Inc. is set to host a virtual event featuring esteemed medical professionals to discuss advancements in the treatment of Eosinophilic Esophagitis (EoE). The event, scheduled for May 29, 2024, will showcase the Company's innovative DiffuSphere™ technology and its promising applications in drug delivery.

Dr. Evan S. Dellon, a renowned expert from the University of North Carolina School of Medicine, will be a key speaker at the event. Dr. Dellon, who chairs the Company's Gastrointestinal Clinical Advisory Board, will provide insights into the unmet needs and current treatment landscape for EoE.

EoE is a chronic, immune-mediated condition characterized by an abnormal accumulation of white blood cells in the esophagus, leading to inflammation and difficulty swallowing. This disease affects over 450,000 individuals in the United States and is becoming increasingly prevalent. The condition significantly impacts patients' quality of life and presents a considerable burden on healthcare systems.

Eupraxia's proprietary technology, DiffuSphere™, aims to revolutionize the treatment of EoE by ensuring targeted drug delivery to the esophagus, potentially enhancing therapeutic outcomes. The KOL event will highlight data from the Phase 1b/2a RESOLVE clinical trial, focusing on the efficacy of EP-104GI in treating EoE. Early results indicate that EP-104GI, utilizing DiffuSphere™ technology, may offer a significant improvement in delivering medication directly to the affected esophageal tissue.

In addition to the formal presentation, the event will include a live question-and-answer session, allowing participants to engage with the experts and Company management.

Dr. Dellon's extensive background in gastroenterology and epidemiology positions him as a leading authority in the field. With degrees from Brown University and Johns Hopkins School of Medicine, and extensive training at Massachusetts General Hospital and UNC, Dr. Dellon has dedicated his career to improving the diagnosis and treatment of EoE and other eosinophilic gastrointestinal diseases (EGIDs). His research focuses on the epidemiology, pathogenesis, and treatment outcomes of these conditions, aiming to enhance patient care and quality of life.

Eupraxia Pharmaceuticals, a clinical-stage biotechnology firm, is dedicated to developing locally delivered, extended-release drugs to address areas of significant medical need. The Company's DiffuSphere™ technology represents a significant advancement in drug delivery, offering prolonged therapeutic effects with reduced side effects. This polymer-based microsphere system can be tailored for various pharmacokinetic profiles and is suitable for multiple active pharmaceutical ingredients and delivery methods.

Recently, Eupraxia completed a Phase 2b clinical trial (SPRINGBOARD) for EP-104IAR, targeting osteoarthritis-related knee pain. The trial achieved its primary endpoint and three out of four secondary endpoints. Building on this success, the Company has expanded the EP-104 platform to address gastrointestinal diseases, with the RESOLVE trial exploring treatments for EoE. Eupraxia is also developing a pipeline of other formulations aimed at conditions such as inflammatory joint diseases and cancer, with the goal of improving efficacy and tolerability compared to existing treatments.

Eupraxia's commitment to advancing medical science and improving patient outcomes is evident in its ongoing research and development efforts. The upcoming KOL event is an opportunity for the medical community to gain insights into the latest advancements and future directions in the treatment of EoE and related conditions.